SCHEMBL25356232

SCHEMBL25356232

COc1cc(F)c(-c2c(F)c(F)c(F)c(F)c2F)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.47
ALDH1A1 P00352 3/20 0.46
CYP1A2 P05177 4/20 0.39
CYP1A1 P04798 3/20 0.39
CYP1B1 Q16678 3/20 0.39
GRM8 O00222 1/20 0.39
GRM7 Q14831 1/20 0.39
NQO2 P16083 1/20 0.35
GRK6 P43250 1/20 0.35
CYP3A4 P08684 3/20 0.34
CPS1 P31327 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
CA14 Q9ULX7 1/20 0.33
FFAR1 O14842 1/20 0.33
FFAR4 Q5NUL3 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2936514 0.92 TAAR1 (0.41) TAAR1ALDH1A1CYP1A2CYP1A1CYP1B1
SCHEMBL2727079 0.87 TAAR1 (0.38) TAAR1ALDH1A1CYP1A2CYP1A1CYP1B1
SCHEMBL2943666 0.86 TAAR1 (0.44) TAAR1ALDH1A1CYP1A2CYP1A1CYP1B1
SCHEMBL2938082 0.85 TAAR1 (0.37) TAAR1ALDH1A1CYP1A2CYP1A1CYP1B1
SCHEMBL2942699 0.84 TAAR1 (0.39) TAAR1ALDH1A1CYP1A2CYP1A1CYP1B1
SCHEMBL2712306 0.82 TAAR1 (0.35) TAAR1ALDH1A1CYP1A2CYP1A1CYP1B1
SCHEMBL2725536 0.82 MAOA (0.35) TAAR1ALDH1A1CYP1A2CYP1A1CYP1B1
SCHEMBL2724680 0.81 MAOA (0.35) TAAR1ALDH1A1CYP1A2CYP1A1CYP1B1
SCHEMBL2943945 0.81 GRM8 (0.39) TAAR1ALDH1A1CYP1A2GRM8GRM7
SCHEMBL2710047 0.80 NQO2 (0.35) TAAR1ALDH1A1CYP1A2CYP1A1CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637438-B2 Protoporphyrinogen oxidase inhibitors ENKO CHEM, INC. (US) 2026-05-26 US disclosed
US-20250084044-A1 PROTOPORPHYRINOGEN OXIDASE INHIBITORS ENKO CHEM, INC. (US) 2025-03-13 US disclosed
US-20230382876-A1 PROTOPORPHYRINOGEN OXIDASE INHIBITORS ENKO CHEM, INC. (US) 2023-11-30 US disclosed
US-20230382876-A1 PROTOPORPHYRINOGEN OXIDASE INHIBITORS ENKO CHEM, INC. (US) 2023-11-30 US disclosed
US-11827610-B2 Protoporphyrinogen oxidase inhibitors ENKO CHEM, INC. (US) 2023-11-28 US disclosed
US-11827610-B2 Protoporphyrinogen oxidase inhibitors ENKO CHEM, INC. (US) 2023-11-28 US disclosed
US-11827610-B2 Protoporphyrinogen oxidase inhibitors ENKO CHEM, INC. (US) 2023-11-28 US disclosed
US-20230265060-A1 PROTOPORPHYRINOGEN OXIDASE INHIBITORS ENKO CHEM, INC. (US) 2023-08-24 US disclosed
US-20230265060-A1 PROTOPORPHYRINOGEN OXIDASE INHIBITORS ENKO CHEM, INC. (US) 2023-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250084044-A1 PROTOPORPHYRINOGEN OXIDASE INHIBITORS PPOX, CYP4X1, PNPO TAAR1 3165/4885ALDH1A1 1008/4885CYP1A2 34/4885
US-12637438-B2 Protoporphyrinogen oxidase inhibitors PPOX, CYP4X1, CBR3 TAAR1 3077/4885ALDH1A1 741/4885CYP1A2 63/4885
US-11827610-B2 Protoporphyrinogen oxidase inhibitors PPOX, PPIF, CYP4X1 TAAR1 4022/4885ALDH1A1 597/4885CYP1A2 27/4885
US-20230265060-A1 PROTOPORPHYRINOGEN OXIDASE INHIBITORS PPOX, PPIF, CYP4X1 TAAR1 4024/4885ALDH1A1 594/4885CYP1A2 27/4885
US-20230382876-A1 PROTOPORPHYRINOGEN OXIDASE INHIBITORS PPOX, PPIF, CYP4X1 TAAR1 4022/4885ALDH1A1 597/4885CYP1A2 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.